BIONDVAX
BiondVax Pharmaceuticals, a publicly-traded company (TASE: BNDX) located in the Weizmann Science Park in Ness-Ziona (Israel), is dedicated to the development of a novel Universal Influenza Vaccine. BiondVax's Universal Flu Vaccine is based on research carried out over a period of 20 years by Weizmann Institute Professor Ruth Arnon, who heads the company's Scientific Advisory Board. Professor Arnon is well-known for her part in the development of Copaxone®, a blockbuster drug for the treatment o... f multiple sclerosis. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing this innovative flu vaccine. BiondVax’s team of 14 includes scientists, technicians, researchers, and administrative staff. The company’s state-of-the-art GMP facility in Ness-Ziona houses its laboratories, production facilities and offices.
BIONDVAX
Industry:
Biotechnology Health Care Information Technology
Founded:
2003-01-01
Address:
Ness Ziona, HaMerkaz, Israel
Country:
Israel
Website Url:
http://www.biondvax.com
Total Employee:
11+
Status:
Active
Contact:
(972) 893-0252
Email Addresses:
[email protected]
Total Funding:
45.49 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Content Delivery Network Euro Microsoft Exchange Online Organization Schema Office 365 Mail
Similar Organizations
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Biocytogen
Biopharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Peptidream
Peptidream is a biopharmaceutical company.
Sinovant Sciences
Sinovant Sciences is an innovative biopharmaceutical company.
YS Biopharma
YS Biopharma is a global, fully integrated bio-pharmaceutical company.
Current Employees Featured
Founder
Stock Details
Investors List
European Investment Bank
European Investment Bank investment in Post-IPO Debt - BiondVax
Office of the Chief Scientist
Office of the Chief Scientist investment in Grant - BiondVax
Official Site Inspections
http://www.biondvax.com Semrush global rank: 7.47 M Semrush visits lastest month: 481
- Host name: 198.185.159.145
- IP address: 198.185.159.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "BiondVax"
About BiondVax — BiondVax Pharmaceuticals Ltd
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company focused on developing, manufacturing, and commercializing …See details»
FAQs 1 - BiondVax Pharmaceuticals Ltd
BiondVax FAQ. When was BiondVax founded, and what has the company achieved? BiondVax was founded in 2003 by Dr. Ron Babecoff, based on technology developed by Copaxone co …See details»
BIONOVA X - DLP 3D Bioprinter - CELLINK
With the BIONOVA X, we are meeting the demand for more precise, biomimetic models for high throughput applications. We’re enabling the effortless recapitulation of microarchitectures, …See details»
BiondVax - Wikiwand
BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing and manufacturing immunotherapeutic products, primarily for the treatment of infectious …See details»
BiondVax Pharmaceuticals Ltd - BIO CEO & Investor Conference
Feb 6, 2023 The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. BiondVax …See details»
BiondVax signs definitive agreements for development and ...
Dec 22, 2021 The collaboration has been facilitated by kENUP, a civic society organization promoting innovative industries in Europe. About BiondVax: BiondVax Pharmaceuticals Ltd. …See details»
BiondVax Signs Deals For Development And Commercialization Of …
Dec 22, 2021 (RTTNews) - BiondVax Pharmaceuticals Ltd. (BVXV) said that it has signed definitive agreements with the Max Planck Society, the parent organization of the Max Planck …See details»
BiondVax Pharma Rebrands as Scinai Immunotherapeutics; …
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company, is pleased to announce today a change of its corporate name to Scinai Immunotherapeutics Ltd. …See details»
Letter from BiondVax's New CEO to Shareholders - Nasdaq
Mar 23, 2021 After many years of pharmaceutical leadership positions in the US and Europe, I jumped at the opportunity to return to my roots in Israel to take over the reins as BiondVax's …See details»
BIONOVA X - Bioprinting with Light - CELLINK
The BIONOVA X light-based bioprinter enables high resolution live cell printing, a new frontier in light-based 3D bioprinting.See details»
BiondVax Files FY 2022 Financial Statements and Annual Report …
Jerusalem, Israel - April 17, 2023 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing …See details»
BiondVax announces financial plans to support its ongoing …
JERUSALEM, Israel , Sept. 30, 2022 /PRNewswire/ --BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and …See details»
BiondVax grows vaccine production with new facility
Jul 19, 2017 Dive Insight: BiondVax is financing the new facility with a grant from Israel's Ministry of Economy and Industry worth a little more than $1 million, as well as a €20 million (about $22 …See details»
BiondVax Announces Appointment of Amir Reichman as New CEO
Jan 21, 2021 Mr. Reichman and Ron Babecoff, BiondVax's founder and current CEO, will share duties during a transition period while Mr. Reichman completes his work obligations at …See details»
BiondVax signs definitive agreements for development and ...
Dec 22, 2021 Jerusalem, Israel – December 22, 2021 – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and …See details»
BiondVax signs definitive agreements for development and ...
JERUSALEM, Dec. 22, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing …See details»
BiondVax receives supportive Scientific Advice from the Paul …
Jun 7, 2022 PEI supports BiondVax's plan for first-in-human clinical trial to be conducted in patients as a combined Phase 1/2a, testing both safety and efficacy, thereby shortening …See details»
Novavax Nuvaxovid COVID-19 vaccine - Canada.ca
Name: Novavax Nuvaxovidâ„¢ COVID-19 vaccine; Novavax Nuvaxovidâ„¢ XBB.1.5 Omicron subvariant COVID-19 vaccine Manufacturer: Novavax Inc. Type: protein-based vaccine …See details»
BiondVax signs definitive collaboration agreement for the …
Mar 24, 2022 The collaboration has been facilitated by kENUP, a civic society organization promoting innovative industries in Europe. About BiondVax: BiondVax Pharmaceuticals Ltd. …See details»